The financing was obtained from existing investors, including Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and the Aurora Funds.
The company plans to use the proceeds raised in this financing to further advance the development of its four clinical-stage product candidates and for general corporate purposes.